New intranasal influenza vaccine triggers robust immunity with significantly less antigenOctober 29, 2008A single administration of a novel, nasally delivered influenza vaccine elicited immune responses in ferrets that were more than 20 times higher than those generated by two injections of the currently approved vaccines, according to a study by NanoBio Corporation. The new vaccine used only half the standard antigen dose to produce this effect. Results of the study are being presented today at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, D.C. The company's nasal vaccines exert adjuvant activity without the need for pro-inflammatory materials, toxins or cytokines. "Our nanoemulsion-based intranasal vaccine adjuvant system represents a paradigm shift in vaccinology. It can be used to safely deliver multiple antigen types directly into the lining of the nasal mucosa, which is rich in dendritic cells that present the antigen(s) to the immune system," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "The nanoemulsion adjuvant uniquely interacts with these cells to trigger unparalleled mucosal and systemic immunity." In the study, ferrets received 7.5, 15 and 45 micrograms of nanoemulsion-adjuvanted influenza vaccine (n=12 ferrets/dose). All three doses produced antibody responses substantially higher than those triggered by the standard intramuscular vaccine. The ferrets, which represent the most relevant influenza animal model for humans, were then challenged with live influenza virus, and all were protected. "A large, unmet medical need still exists for protecting people from influenza infection," Baker said. "The robust immunity and antigen-sparing capability demonstrated in this study are especially important for addressing this unmet need, as are the demands for a vaccine that would protect people in the face of a flu pandemic." NanoBio plans to begin a phase 1 clinical study for seasonal influenza in the first half of 2009 and is currently initiating preclinical studies in pandemic flu. MedThink Communications |
|||||||||||||||||||||
| Related Influenza Vaccine Current Events and Influenza Vaccine News Articles Initial Results Show Pregnant Women Mount Strong Immune Response To One Dose of 2009 H1N1 Flu Vaccine Healthy pregnant women mount a robust immune response following just one dose of 2009 H1N1 influenza vaccine, according to initial results from an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. Flu vaccine given to women during pregnancy keeps infants out of the hospital Infants born to women who received influenza vaccine during pregnancy were hospitalized at a lower rate than infants born to unvaccinated mothers. Flu shots not to be sneezed at Two in five at-risk American adults who would benefit from vaccination against seasonal flu are missing out on the protective shots because they believe they do not need them and are not inclined to be vaccinated. NIH launches 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched yesterday, and a trial to conduct the same test in HIV-infected children and youth will begin next week. NIH prepares to launch 2009 H1N1 influenza vaccine trial in people with asthma The National Institutes of Health is preparing to launch the first government-sponsored clinical trial to determine what dose of the 2009 H1N1 influenza vaccine is needed to induce a protective immune response in people with asthma, especially those with severe disease. Early results: In children, 2009 H1N1 influenza vaccine works like seasonal flu vaccine Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising, according to the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults We are encouraged by reports that are now emerging from various clinical trials of 2009 H1N1 influenza vaccines, conducted by various vaccine manufacturers. GEN reports on efforts to quickly develop swine flu vaccine Scientists around the world are accelerating their efforts to develop a vaccine against the H1N1 influenza virus (Swine flu) as rapidly as possible, reports Genetic Engineering & Biotechnology News (GEN). Universal flu vaccine holds promise An influenza vaccine that protects against death and serious complications from different strains of flu is a little closer to reality, Saint Louis University vaccine researchers have found. Flu virus foiled again Researchers at The Scripps Research Institute in La Jolla, California, supported in part by the National Institutes of Health, have identified a common Achilles' heel in a wide range of seasonal and pandemic influenza A viruses. More Influenza Vaccine Current Events and Influenza Vaccine News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||